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even in a clone that is not part of the malignant 
process) can have an effect on clinical responses. 
The serial tracking of TP53 mutation clearance in 
our study gave us confidence that the TP53 muta-
tions that we detected were in fact relevant for 
pathogenesis and responses.
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Levosimendan in Sepsis
To the Editor: Like many critical care physicians, 
we excitedly awaited the results of the Levosi-
mendan for the Prevention of Acute Organ Dys-
function in Sepsis (LeoPARDS) trial by Gordon 
et al. (Oct. 27 issue)1 to find out whether to use 
levosimendan in hemodynamically unstable pa-
tients with sepsis. The rationale for using levosi-
mendan in sepsis is based on studies that have 
shown a mortality benefit among patients with 
septic cardiomyopathy who were treated with le-
vosimendan.2,3
Unfortunately, the number of patients with 
myocardial dysfunction who were included in the 
LeoPARDS trial was evidently rather low, accord-
ing to the sparse hemodynamic information (only 
30% of the patients underwent baseline cardiac-
output assessment), the liberal inclusion criteria, 
and the negligible use of dobutamine. In addition, 
neither routine echocardiography nor hemody-
namic monitoring was required during the 
course of the trial. Therefore, this trial does not 
add more than the information that patients with 
sepsis who presented with reduced systemic vas-
cular resistance but without clinical signs of myo-
cardial dysfunction did not benefit from treat-
ment with a potent inodilator drug. Thus, rather 
disappointingly, the trial design was too simple 
to answer the question of whether “to use or not 
to use” levosimendan in patients with hemody-
namically relevant septic cardiomyopathy.
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To the Editor: The results of the LeoPARDS 
trial of levosimendan in patients with sepsis sug-
gest no beneficial effects on clinical outcomes. 
Early treatment is a cornerstone of sepsis ther-
apy, and a meta-analysis of randomized trials sup-
ported a beneficial effect of levosimendan among 
patients with sepsis who had a rate of death of up 
to 60%,1 which suggests that high-risk patients 
with septic shock may receive the greatest benefit 
from levosimendan infusion. Gordon et al. enrolled 
low-risk patients relatively late after the diagno-
sis of septic shock without confirmed concomi-
tant cardiac dysfunction and administered a high 
dose of levosimendan (up to 0.2 μg per kilogram 
of body weight per minute), which induced tachy-
cardia and hypotension. Under these conditions, 
the authors found no difference in survival with 
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levosimendan as compared with placebo. None-
theless, pragmatic, multicenter, randomized, 
controlled trials represent the best available de-
sign to test treatments,2 and all previous evidence 
on mortality reduction with levosimendan in pa-
tients with sepsis and those undergoing surgery 
was based on poor-quality single-center, random-
ized, controlled trials. Results of two large, multi-
center, randomized, controlled trials on periop-
erative use of levosimendan3,4 are awaited to see 
whether this drug is only an inotropic agent or 
can also improve survival.
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To the Editor: In the LeoPARDS trial, no bene-
fit was found with the addition of levosimendan 
to standard treatment in terms of organ dysfunc-
tion and mortality among patients with sepsis. 
The results of this trial are not surprising, since 
levosimendan, as a myofilament Ca2+-sensitizing 
positive inotropic drug, should be reserved for 
patients with sepsis who have signs of myocar-
dial dysfunction. Otherwise, only deleterious 
effects can be expected for the drug because of 
its vasodilating properties. Surprisingly, in the 
LeoPARDS trial, there was no echocardiographic 
evaluation to identify patients who could have 
benefited from the inotropic effect of levosimen-
dan. The authors report that even in the subset of 
patients with a low cardiac index, the drug pro-
vided no benefit. However, during sepsis, a low 
cardiac output cannot be considered synonymous 
with altered cardiac contractility without echo-
cardiographic assessment. The fact that even in 
this subgroup of patients cardiac output did not 
increase with the drug confirms this lack of cor-
relation.
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To the Editor: In the LeoPARDS trial, levosi-
mendan was added to standard care to reduce 
the severity of organ dysfunction in sepsis. Previ-
ous studies,1-4 in which more severely ill patients 
were enrolled, focused on the effects of levosi-
mendan on organ perfusion rather than func-
tion, and improved organ perfusion was observed 
with improved systemic hemodynamics when ad-
ditional volume was administered. In our view, the 
patients in the LeoPARDS trial were not receiving 
sufficient volume loading during levosimendan 
infusion, which led to relative hypovolemia, 
causing tachycardia, supraventricular arrhythmia, 
and eventually decreased organ perfusion. In this 
trial, the central venous oxygen saturation was 
significantly higher after 24 hours in the levosi-
mendan group than in the placebo group, de-
spite a significantly lower ratio of partial pres-
sure of arterial oxygen to fractional inspired 
oxygen and an unchanged cardiac index. In addi-
tion, lactate levels tended to be lower. These 
findings suggest that even under the worst he-
modynamic conditions, levosimendan was still 
effective in improving microcirculation. The re-
sults of the LeoPARDS trial strengthen the im-
portance of providing adequate volume before 
the administration of levosimendan for improv-
ing systemic hemodynamics, tissue perfusion, 
and, potentially, function in patients with sepsis.
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The authors reply: We disagree with Putzu et 
al. that low-risk patients were enrolled late after 
the diagnosis of septic shock in our trial. The 
median dose of norepinephrine (0.28 μg per kilo-
gram per minute) and a rate of death of 31% at 
28 days in the placebo group — a rate that is 
markedly higher than that in recent trials of ear-
ly goal-directed therapy among patients in early 
septic shock1 — suggest that most patients were 
not at low risk. Patients had to still be in shock 
at the time of randomization to ensure that 
those who had already been treated successfully 
were not included in the trial. Similar results 
were seen in the highest-risk subgroups (lactate 
level, >2 mmol per liter; and norepinephrine 
dose, >0.28 μg per kilogram per minute), among 
whom 28-day mortality was up to 40%.
Groesdonk et al. question the level of hemo-
dynamic monitoring, and Morelli and Tritapepe 
discuss the patients’ intravascular volume status. 
Sites were encouraged to use their routine clini-
cal monitoring practices for septic shock to en-
sure that all patients had received adequate fluid 
resuscitation before inclusion and that these mea-
sures were repeatedly reassessed. Arterial and 
central venous catheters were standard, but 
cardiac-output monitoring was not mandated. 
As pointed out by Hamzaoui and Teboul, simple 
cardiac-output monitoring may not be sufficient 
to fully assess myocardial dysfunction. Echocar-
diography provides the most detailed assessment 
of altered cardiac contractility, but its use requires 
expert hands. Measurements are user-dependent, 
especially when made by less experienced staff 
members. A strong supportive evidence base for 
echocardiography is lacking, and the risk of mis-
interpretation exists.2 More objective assessments 
of ventricular dysfunction, such as total isovole-
mic time and strain-rate imaging using speckle-
tracking echocardiography (which characterizes 
and measures myocardial deformation),3 are cer-
tainly not within the scope of a clinician with 
basic echocardiographic training and thus are 
not suitable to use for inclusion in a large, multi-
center clinical trial.
Studies have shown that myocardial dysfunc-
tion is present in up to 60% of the patients with 
septic shock and may not be apparent at initial 
presentation.3,4 Therefore, the majority of pa-
tients with septic shock could still be expected 
to benefit from the inotropic effects of levosi-
mendan, not to mention its antiinflammatory, 
antioxidative, antiapoptotic, and cardioprotective 
effects.5 Such effects may offer additional sys-
temic benefit, regardless of the presence of myo-
cardial dysfunction. We did not see any benefit 
from levosimendan in the predefined subgroups 
of patients with a low cardiac index (≤2.44 liters 
per minute per square meter of body-surface 
area) or those with impaired oxygen delivery 
(central venous oxygen saturation, <70%) nor in 
the post hoc subgroup of patients being treated 
with an inotrope at inclusion, findings that are 
consistent with the results in the whole population.
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